Omapatrilat vasopeptidase inhibitor

Description Results NMA

hospitalization for heart failure 0.44 [0.19; 0.99]

death or hospitalization for heart failure 0.52 [0.27; 1.00]

all cause death 0.69 [0.27; 1.78]

omapatrilat 40 mg once dailyitm (n=2886)

vs.

enalapril 10 mg twice daily (n=2884)

double blind

Parallel groups

Sample size: 2886/2884

Primary endpoint: death or hospitalization for HF requiring intravenous treatment

FU duration: 14.5 months

omapatrilat target dose 40 mg daily (n=289)

vs.

lisinopril target dose 20mg daily (n=284)

double blind

Parallel groups

Sample size: 289/284

Primary endpoint: improvement in maximum exercise treadmill test

FU duration: 12 weeks (24 weeks)